Common pathophysiology affecting diabetic retinopathy and Parkinson's disease

Medical Hypotheses

Volumn 85, Issue 4, 2015, Pages 397-398

  Tian, Tian ^a   Li, Zhaoming ^a   Lu, Hong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; TYROSINE 3 MONOOXYGENASE; GLUCOSE BLOOD LEVEL;

ARTICLE; COMORBIDITY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DOPAMINE DEFICIENCY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOWN REGULATION; HUMAN; INCIDENCE; METABOLIC DISORDER; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; RETINA AMACRINE CELL; RISK FACTOR; SUBSTANTIA NIGRA; ANIMAL; COMPLICATION; DISEASE COURSE; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MESENCEPHALON; METABOLISM; MOUSE; RETINA; THEORETICAL MODEL;

ALPHA-SYNUCLEIN; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; MESENCEPHALON; MICE; MODELS, THEORETICAL; PARKINSON DISEASE; RETINA; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84942500172     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.06.016     Document Type: Article

References (25)

1. Sivaprasad S., Gupta B., Crosby-Nwaobi R., Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol 2012, 57:347-370.
2. Frank R.N. Diabetic retinopathy. N Engl J Med 2004, 350:48-58.
3. Forbes J.M., Cooper M.E. Mechanisms of diabetic complications. Physiol Rev 2013, 93:137-188.
4. Marozas L.M., Fort P.E. Diabetic retinopathy - update on prevention techniques, present therapies, and new leads. US Ophthalmic Rev 2014, 7:54-58.
5. Giusti C., Gargiulo P. Advances in biochemical mechanisms of diabetic retinopathy. Eur Rev Med Pharmacol Sci 2007, 11:155-163.
6. Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy. N Engl J Med 2012, 366:1227-1239.
7. Jackson G.R., Barber A.J. Visual dysfunction associated with diabetic retinopathy. Curr Diab Rep 2010, 10:380-384.
8. Bearse M.A., Han Y., Schneck M.E., Adams A.J. Retinal function in normal and diabetic eyes mapped with the slow flash multifocal electroretinogram. Invest Ophthalmol Vis Sci 2004, 45:296-304.
9. Fletcher E.L., Phipps J.A., Ward M.M., Puthussery T., Wilkinson-Berka J.L. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des 2007, 13:2699-2712.
10. Nishimura C., Kuriyama K. Alterations in the retinal dopaminergic neuronal system in rats with streptozotocin-induced diabetes. J Neurochem 1985, 45:448-455.
11. Gastinger M.J., Singh R.S., Barber A.J. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 2006, 47:3143-3150.
12. Boeve B.F. Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol 2013, 12:469-482.
13. Ola M.S., Alhomida A.S. Neurodegeneration in diabetic retina and its potential drug targets. Curr Neuropharmacol 2014, 12:380-386.
14. Lieth E., Barber A.J., Xu B., Dice C., Ratz M.J., Tanase D., et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998, 47:815-820.
15. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998, 102:783-791.
16. Mohr S., Xi X., Tang J., Kern T.S. Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes 2002, 51:1172-1179.
17. Xu Q., Park Y., Huang X., Hollenbeck A., Blair A., Schatzkin A., et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011, 34:910-915.
18. Fatima S., Haque R., Jadiya P., Shamsuzzama, Kumar L., Nazir A. Ida-1, the Caenorhabditis elegans orthologue of mammalian diabetes autoantigen IA-2, potentially acts as a common modulator between Parkinson's disease and diabetes: role of Daf-2/Daf-16 insulin like signalling pathway. PLoS One 2014, 9:e113986.
19. Aviles-Olmos I., Limousin P., Lees A., Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013, 136:374-384.
20. Björklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007, 30:194-202.
21. Jackson C.R., Ruan G.X., Aseem F., Abey J., Gamble K., Stanwood G., et al. Retinal dopamine mediates multiple dimensions of light-adapted vision. J Neurosci 2012, 32:9359-9368.
22. Seki M., Tanaka T., Nawa H., Usui T., Fukuchi T., Ikeda K., et al. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004, 53:2412-2419.
23. Aung M.H., Park H.N., Han M.K., Obertone T.S., Abey J., Aseem F., et al. Dopamine deficiency contributes to early visual dysfunction in a rodent model of type 1 diabetes. J Neurosci 2014, 34:726-736.
24. Aviles-Olmos I., Dickson J., Kefalopoulou Z., Djamshidian A., Ell P., Soderlund T., et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013, 123:2730-2736.
25. Martínez-Navarrete G.C., Martín-Nieto J., Esteve-Rudd J., Angulo A., Cuenca N. Alpha synuclein gene expression profile in the retina of vertebrates. Mol Vis 2007, 13:949-961.